Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.

Autor: Lauro A; Liver and Multiorgan Transplant Unit, S.Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. augustola@yahoo.com, Amaduzzi A, Dazzi A, Ercolani G, Zanfi C, Golfieri L, Grazi GL, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Siniscalchi A, Faenza S, D'Errico A, Di Simone M, Pironi L, Pinna AD
Jazyk: angličtina
Zdroj: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2007 Mar; Vol. 39 (3), pp. 253-6. Date of Electronic Publication: 2007 Feb 01.
DOI: 10.1016/j.dld.2006.11.012
Abstrakt: Introduction: Induction therapy has been recently adopted for intestinal transplant.
Patients and Methods: We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax) or Alemtuzumab (Campath-1H).
Results: During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection.
Discussion and Conclusions: Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month.
Databáze: MEDLINE
Externí odkaz: